TERT and colorectal cancer: Interestingly, an oxaliplatin-resistant colorectal cancer cell line was shown to express increased TERT levels [84]; this suggests that the input of another effective cytotoxic drug to manage chemoresistant tumor cells may facilitate anti-TERT immunity and possibly activate novel CD4 T cell clones.